BioMarin Withdraws European Application for Kyndrisa - Genetic Engineering & Biotechnology News

Tech Times

BioMarin Withdraws European Application for Kyndrisa Genetic Engineering & Biotechnology News BioMarin Pharmaceutical said today it has withdrawn its Marketing Authorization Application (MAA) for Kyndrisa™ (drisapersen), the company's drug candidate for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. BioMarin said it will also ... BioMarin Withdraws Kyndrisa Marketing Application in EUZacks.com Business News Roundup, June 1SFGate BioMarin To Halt Development Of $680M Duchenne Muscular Dystrophy DrugTech Times all 24 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGmrV6dTzgxyu22M_4OQy7ryn_bcg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779124020706&ei=Z_ZOV9i1KouP3AGV9ITQAQ&url=http://www.genengnews.com/gen-news-highlights/biomarin-withdraws-european-application-for-kyndrisa/81252778/
via IFTTT